Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines.

Blood - 27 Aug 2009

Jedidi Abire, Marty Caroline, Oligo Charleen, Jeanson-Leh Laurence, Ribeil Jean-Antoine, Casadevall Nicole, Galy Anne, Vainchenker William, Villeval Jean-Luc

Abstract excerpt

The JAK(V617F) mutation is responsible for the majority of breakpoint cluster region (BCR)/Abelson (ABL)-negative myeloproliferative disorders. Ongoing clinical trials of Janus kinase 2 (JAK2) inhibitors in myeloproliferative disorder patients use small molecules targeting both wild-type and mutated JAK2. To selectively target malignant cells, we developed JAK2(V617F)-specific small interfering RNAs or short...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Cytokines

Share to Janus Kinase 2

Share to K562 Cells

Share to RNA Interference

Share to RNA, Small Interfering

Source

Identifiers

PMID: 19589925
DOI: 10.1182/blood-2008-09-176875

Genes

JAK2
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines.PMID 19589925Read ↗

Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)Semantic proximity Read ↗

Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?Semantic proximity Read ↗

Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.Semantic proximity Read ↗

JAK2V617F-dependent down regulation of SHP-1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF-β.Semantic proximity Read ↗

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alphaSemantic proximity Read ↗

Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.Semantic proximity Read ↗

RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosisSemantic proximity Read ↗

Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.Semantic proximity Read ↗

Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.Semantic proximity Read ↗

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.Semantic proximity Read ↗

Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.Semantic proximity Read ↗

Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.